Rani Therapeutics RANI 深 滬
已收盤 08-07 16:00:00 美东时间
0.792
+0.011
+1.40%
華盛通- 最 高0.80
- 今 開0.7849
- 成交量 20.21万股
- 最 低 0.7822
- 昨 收 0.7811
- 總市值 1.08亿
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 0.4404
- 委 比 37.59%
- 總股本 1.36亿
- 歷史最高 36.27
- 量 比 0.28
- 振 幅 2.28%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Rani Therapeutics appoints Michelle Gilson to its Board of Directors, where she will serve as Chair of the Audit Committee. Gilson, former CFO of Arcellx, brings extensive capital markets and biotech financial leadership experience. Her expertise in financial strategy and corporate governance is expected to support Rani's growth and strategic initiatives. Gilson's background includes leading Arcellx through its acquisition by Gilead and collabora...
08-04 12:00
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics granted Nicholas Maestas, its new CFO, a stock option to purchase 2,000,000 shares of Class A common stock with an exercise price of $0.6973 per share. The option vests over four years, with 25% vesting after the first year and the remaining shares vesting quarterly over the next three years. The grant was approved by the Compensation Committee under the 2026 Equity Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4...
07-20 20:05
派格生物医药-B盘中大涨超22% 牵手Rani推进多项代谢创新资产口服化
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 派格生物医药-B（02565）早盘一度大涨超22%，截至发稿，股价上涨15....
07-10 09:56
派格生物（02565）牵手Rani：口服化打开下一代代谢资产的全球重估空间
在核心产品维培那肽进入商业化阶段后，派格生物正在为其下一代代谢创新管线叠加新的产品形态和海外开发路径。 近日，港股上市公司派格生物（02565）与美国纳斯达克上...
07-10 08:45
派格生物：与纳斯达克上市公司Rani Therapeutics签署谅解备忘录
7月10日，派格生物医药-B（02565.HK）公告，公司于2026年7月8日与美国纳斯达克上市公司Rani Therapeutics（RANI.US） Ho...
07-10 08:17
Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill Platform
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced a research and development collaboration with PegBio Co., Ltd. ("PegBio") to explore the delivery of multiple...
07-10 04:07
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Rani Therapeutics appoints Nicholas Maestas as Chief Financial Officer, effective immediately. Maestas brings over 10 years of financial leadership experience in biotechnology, including roles at Tempest Therapeutics and Alector. He succeeds Svai Sanford, who is departing for another opportunity. Maestas expressed enthusiasm for advancing Rani's oral delivery platform technology, RaniPill®, to address the challenge of effective oral delivery of b...
06-29 12:00
GLP-1/GLP-2双激动剂，治疗肥胖：拿到新一轮融资
注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 药融...
06-04 17:12
